{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:19:56Z","timestamp":1791652796086,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T00:00:00Z","timestamp":1659830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T00:00:00Z","timestamp":1659830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40257-022-00708-w","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T14:02:18Z","timestamp":1659880938000},"page":"719-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-0007","authenticated-orcid":false,"given":"Alan","family":"Menter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravan Kumar","family":"Eduru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Buschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"Liesenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schaible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,7]]},"reference":[{"issue":"3","key":"708_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","volume":"72","author":"T D\u00f6rner","year":"2013","unstructured":"D\u00f6rner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72(3):322\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"708_CR2","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","volume":"75","author":"T D\u00f6rner","year":"2016","unstructured":"D\u00f6rner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75(6):974\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"708_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrd2196","volume":"6","author":"V Strand","year":"2007","unstructured":"Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov. 2007;6(1):75\u201392.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"708_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjd.17335","volume":"180","author":"AG Ellis","year":"2019","unstructured":"Ellis AG, Flohr C, Drucker AM. Network meta-analyses of systemic treatments for psoriasis: a critical appraisal. Br J Dermatol. 2019;180(2):282\u20138.","journal-title":"Br J Dermatol"},{"key":"708_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/JIR.S165330","volume":"11","author":"P Rawla","year":"2018","unstructured":"Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res. 2018;11:215\u201326.","journal-title":"J Inflamm Res"},{"key":"708_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2147\/CEOR.S140063","volume":"9","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. Clinicoecon Outcomes Res. 2017;9:573\u201384.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"2","key":"708_CR7","first-page":"54","volume":"44","author":"J Smeeding","year":"2019","unstructured":"Smeeding J, Malone DC, Ramchandani M, Stolshek B, Green L, Schneider P. Biosimilars: considerations for payers. Pharm Ther. 2019;44(2):54\u201363.","journal-title":"Pharm Ther"},{"key":"708_CR8","unstructured":"FDA. Biosimilar and Interchangeable Products. 2017. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-and-interchangeable-products. Accessed May 2021."},{"issue":"12","key":"708_CR9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/13543784.2016.1255724","volume":"25","author":"C Wynne","year":"2016","unstructured":"Wynne C, Altendorfer M, Sonderegger I, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE\u00ae-PK) in healthy subjects. Expert Opin Investig Drugs. 2016;25(12):1361\u201370.","journal-title":"Expert Opin Investig Drugs."},{"issue":"6","key":"708_CR10","first-page":"914","volume":"77","author":"SB Cohen","year":"2018","unstructured":"Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77(6):914\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"708_CR11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/14712598.2019.1645114","volume":"19","author":"SB Cohen","year":"2019","unstructured":"Cohen SB, Czeloth N, Lee E, Klimiuk PA, Peter N, Jayadeva G. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext). Expert Opin Biol Ther. 2019;19(10):1097\u2013105.","journal-title":"Expert Opin Biol Ther"},{"key":"708_CR12","unstructured":"FDA. Cyltezo\u00ae Prescribing Information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761058lbl.pdf. Accessed 5 Oct 2021."},{"issue":"1","key":"708_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/14712598.2021.1851362","volume":"21","author":"A Menter","year":"2021","unstructured":"Menter A, Arenberger P, Balser S, et al. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. Expert Opin Biol Ther. 2021;21(1):87\u201396.","journal-title":"Expert Opin Biol Ther"},{"key":"708_CR14","unstructured":"FDA. Cyltezo\u00ae press release. 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-cyltezo-first-interchangeable-biosimilar-humira. Accessed Oct 2021."},{"key":"708_CR15","unstructured":"FDA. Considerations in demonstrating interchangeability with a reference product. 2019. https:\/\/www.fda.gov\/media\/124907\/download. Accessed June 2021."},{"key":"708_CR16","unstructured":"FDA. SEMGLEE\u00ae Prescribing Information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761201Orig1s000lbl.pdf. Accessed Oct 2021."},{"key":"708_CR17","unstructured":"Center for Drug Evaluation and Research. List of licensed biological products with (1) reference product exclusivity and (2) biosimilarity or interchangeability evaluations to date. https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/Biosimilars\/UCM560162.pdf. Accessed June 2021."},{"key":"708_CR18","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40259-020-00446-7","volume":"34","author":"DF Alvarez","year":"2020","unstructured":"Alvarez DF, Wolbink G, Cronenberger C, Orazem J, Kay J. Interchangeability of biosimilars: what level of clinical evidence is needed to support the interchangeability designation in the United States? BioDrugs. 2020;34:723\u201332.","journal-title":"BioDrugs"},{"issue":"11","key":"708_CR19","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1111\/bcp.14330","volume":"86","author":"J Kang","year":"2020","unstructured":"Kang J, Eudy-Byrne RJ, Mondick J, Knebel W, Jayadeva G, Liesenfeld KH. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity. Br J Clin Pharmacol. 2020;86(11):2274\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"708_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/jdv.15174","volume":"33","author":"MT Wan","year":"2019","unstructured":"Wan MT, Alvarez J, Shin DB, Dommasch ED, Wu JJ, Gelfand JM. Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences. J Eur Acad Dermatol Venereol. 2019;33(1):42\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"708_CR21","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s12325-018-0742-9","volume":"35","author":"S Numan","year":"2018","unstructured":"Numan S, Faccin F. Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: systematic review of randomized controlled trials and real-world studies. Adv Ther. 2018;35(9):1295\u2013332.","journal-title":"Adv Ther"},{"issue":"1","key":"708_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","volume":"34","author":"V Strand","year":"2020","unstructured":"Strand V, Gon\u00e7alves J, Hickling TP, Jones HE, Marshall L, Isaacs JD. Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs. 2020;34(1):27\u201337.","journal-title":"BioDrugs"},{"issue":"2","key":"708_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","volume":"17","author":"V Strand","year":"2021","unstructured":"Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol. 2021;17(2):81\u201397.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"708_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/jdv.13884","volume":"31","author":"NM Mostafa","year":"2017","unstructured":"Mostafa NM, Nader AM, Noertersheuser P, Okun M, Awni WM. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(3):490\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"708_CR25","first-page":"345","volume":"4","author":"EA Alwawi","year":"2008","unstructured":"Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther Clin Risk Manag. 2008;4(2):345\u201351.","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"708_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/apt.13992","volume":"45","author":"MG Ward","year":"2017","unstructured":"Ward MG, Thwaites PA, Beswick L, et al. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn\u2019s disease. Aliment Pharmacol Ther. 2017;45(8):1135\u201345.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00708-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T15:11:59Z","timestamp":1667229119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00708-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,7]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00708-w","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,7]]},"assertion":[{"value":"20 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A peer-reviewed video abstract was retrospectively added to this publication.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alan Menter received grant support from AbbVie, Argenx, Novartis, Pfizer, Sun Pharma, and UCB; he reported consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Biocon, Janssen Biotech, LEO Pharma, Novartis, Sun Pharma, and UCB; honoraria for lectures\/presentations\/speaker bureaus from AbbVie, Amgen, Eli Lilly, Janssen, Sun Pharma, and UCB; travel support from Boehringer Ingelheim, Eli Lilly, and Sun Pharma; and participated in data safety monitoring\/advisory boards for Amgen and Boehringer Ingelheim. Stanley Cohen received grant support from AbbVie, Amgen, BMS, Genentech, Lilly, Pfizer, and Roche; he reported consulting fees from AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Genentech, and Pfizer; honoraria from Novartis and Pfizer; and participated in a data safety monitoring board for Gilead Sciences. Jonathan Kay received grant support from Aker BioMarine, Alliance for Lupus Research, AMPEL BioSolutions, Gilead Sciences, Novartis, Pfizer, and UCB; he reported royalty fees from UpToDate; consulting fees from AbbVie, Alvotech, Boehringer Ingelheim, Celltrion Healthcare, Horizon Therapeutics, Jubilant Radiopharma, Merck Sharp & Dohme, Mylan, Novartis, Pfizer, Samsung Bioepis, Sandoz, Scipher Medicine, and UCB; and participated in data safety\/advisory boards for Bristol Myers Squibb, Inmagene, and Kolon TissueGene. Vibeke Strand reported consulting fees from AbbVie, Amgen, Arena, Aria, AstraZeneca, Bayer, Bioventus, BMS, Boehringer Ingelheim, Celltrion, Chemocentryx, EMD Serono, Flexion, Galapagos, Genentech\/Roche, Gilead, GSK, Horizon, Ichnos, Inmedix, Janssen, Kiniksa, Eli Lilly, Merck, MiMedx, Novartis, Pfizer, Regeneron, Rheos, R-Pharma, Samsung, Sandoz, Sanofi, Scipher, Servier, Setpoint, Sun Pharma, Tonix, and UCB. Alice Gottlieb received honoraria as an advisory board member and consultant for AnaptsysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb Co., GSK, Janssen, Eli Lilly, Leo, Novartis, Pfizer, Sun Pharmaceuticals, UCB, Dermavant, and Xbiotech; and received research\/educational grants from Boehringer Ingelheim, Janssen, Novartis, UCB, and Sun Pharmaceutical Industries, Inc. Stephen Hanauer received grant support from AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, and UCB; he reported consultancy fees from AbbVie, Allergan, Amgen, Arena, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cosmos, Catalys Pacific, Covance, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Sorriso, Takeda, TLL Pharma, UCB, and VHSquared; speaker fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; and participated in data safety monitoring boards for Arena, Boehringer Ingelheim; Bristol Myers Squibb, Gossamer, Prometheus, and Protagonist. Susanne Buschke, Karl-Heinz Liesenfeld, Jennifer Schaible, Dorothy McCabe, and Benjamin Lang reported being employees of Boehringer Ingelheim. Sravan\u00a0Kumar\u00a0Eduru was previously employed by Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the applicable independent ethics committee or institutional review board at each participating site, and the trial was performed in accordance with Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from all patients before their participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have reviewed the final version of this manuscript and approved its publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}